20cm速递｜科创创新药ETF国泰（589720）连续10日资金净流入近4亿元，资金积极布局，创新浪潮持续涌动

Group 1 - The core viewpoint is that the Chinese pharmaceutical industry has completed a transformation of growth drivers from 2015 to 2025, with innovation significantly opening new growth avenues for Chinese pharmaceutical companies [1] - The innovation sector in China has reached a scale where traditional pharmaceutical companies have successfully transformed, and their ability to expand internationally has accelerated, making them a key source of innovation for multinational pharmaceutical companies [1] - On the demand side, the aging population is accelerating, leading to increased demand for chronic disease management; on the payment side, health insurance revenue is steadily growing, and the National Healthcare Security Administration is actively promoting the development of commercial insurance to build a multi-tiered payment system [1] Group 2 - New technologies are accelerating industry transformation, with advancements in AI, brain-computer interfaces, early cancer screening, and AI healthcare rapidly developing [1] - The Guotai Innovation Drug ETF (589720) tracks the Innovation Drug Index (950161), which has a daily price fluctuation limit of 20%, focusing on the research and development of new drugs driven by technological innovation [1] - The index emphasizes high R&D investment and innovation capability, favoring allocations in high-tech pharmaceutical sectors such as biopharmaceuticals and chemical pharmaceuticals to reflect market performance and development trends in these areas [1]